arrow
S

Stephen Chan

pennsylvania commonwealth system of higher education (pcshe)
H指数:59
被引数:1.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PARTNER Trial: Neoadjuvant olaparib in triple negative breast cancer (TNBC)
2024-04-050
PRE
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
2023-03-027
OAAI
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+and androgen receptor-positive metastatic or locally advanced breast cancer

恩扎鲁胺联合曲妥珠单抗治疗HER2和雄激素受体阳性转移性或局部晚期乳腺癌的疗效和安全性

2021-02-1623
OAAI
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
2020-05-29174
OAAI
Clinically significant changes of receptors status (ER, PR and HER2) after receiving neoadjuvant chemotherapy (NACT) in breast cancer (BC) predicts the prognosis and guides the choice of the optimal adjuvant therapy (AT): Retesting of the receptor status should be mandatory
2020-02-151
PRE